TaiMed Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	611.35	610.16	491.78	563.01	413.44
Revenue Growth (YoY)	0.19%	24.07%	-12.65%	36.18%	-42.77%
Cost of Revenue	351.9	398.94	266.54	347.3	329.49
Gross Profit	259.45	211.23	225.23	215.71	83.96
Selling, General & Admin	72.26	75.29	97.19	74.45	109.72
Research & Development	381.84	388.21	294.28	333.12	460.6
Operating Expenses	454.1	463.49	391.46	407.57	570.32
Operating Income	-194.65	-252.27	-166.23	-191.86	-486.37
Interest Expense	-10.71	-12.6	-14.81	-10.1	-7.44
Interest & Investment Income	28.94	33.97	8.46	4.34	4.03
Currency Exchange Gain (Loss)	6.49	26.35	2.04	48.69	-11.38
Other Non Operating Income (Expenses)	4.46	5.05	4.78	2.44	3.45
EBT Excluding Unusual Items	-165.48	-199.51	-165.76	-146.48	-497.7
Gain (Loss) on Sale of Investments	-0.69	-	-29.05	-122.81	26.76
Gain (Loss) on Sale of Assets	-1.61	-2.32	-	-	0.01
Pretax Income	-167.78	-201.83	-194.81	-269.29	-470.93
Net Income	-167.78	-201.83	-194.81	-269.29	-470.93
Net Income to Common	-167.78	-201.83	-194.81	-269.29	-470.93
Shares Outstanding (Basic)	273	268	253	252	252
Shares Outstanding (Diluted)	273	268	253	252	252
Shares Change (YoY)	1.85%	6.08%	0.18%	0.04%	0.03%
EPS (Basic)	-0.61	-0.75	-0.77	-1.07	-1.87
EPS (Diluted)	-0.61	-0.75	-0.77	-1.07	-1.87
Free Cash Flow	168.48	-387.61	-31.75	-608.77	-220.96
Free Cash Flow Per Share	0.62	-1.45	-0.13	-2.41	-0.88
Gross Margin	42.44%	34.62%	45.80%	38.31%	20.31%
Operating Margin	-31.84%	-41.34%	-33.80%	-34.08%	-117.64%
Profit Margin	-27.44%	-33.08%	-39.61%	-47.83%	-113.90%
Free Cash Flow Margin	27.56%	-63.52%	-6.46%	-108.13%	-53.44%
EBITDA	-46.5	-104.49	-17.72	-42.22	-336.3
EBITDA Margin	-7.61%	-17.13%	-3.60%	-7.50%	-81.34%
D&A For EBITDA	148.15	147.78	148.51	149.64	150.07
EBIT	-194.65	-252.27	-166.23	-191.86	-486.37
EBIT Margin	-31.84%	-41.34%	-33.80%	-34.08%	-117.64%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.